Versant Ventures V, LLC - Aug 8, 2025 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)

Role
10%+ Owner
Signature
Versant Ventures V, LLC, By /s/ Max Eisenberg, Chief Operating Officer
Stock symbol
TSBX
Transactions as of
Aug 8, 2025
Transactions value $
$0
Form type
4
Date filed
8/12/2025, 04:34 PM
Previous filing
Jul 27, 2023
SEC
View on sec.gov

Reporting Owners (10)

Name Relationship Address Signature Signature date CIK
Versant Ventures V, LLC 10%+ Owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO Versant Ventures V, LLC, By /s/ Max Eisenberg, Chief Operating Officer 2025-08-12 0001619298
Versant Venture Capital V, L.P. 10%+ Owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO Versant Venture Capital V, L.P., By Versant Ventures V, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2025-08-12 0001589097
Versant Ophthalmic Affiliates I, L.P. 10%+ Owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO Versant Ophthalmic Affiliates Fund I, L.P., By Versant Ventures V, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2025-08-12 0001589098
Versant Affiliates Fund V, L.P. 10%+ Owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO Versant Affiliates Fund V, L.P., By Versant Ventures V, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2025-08-12 0001589095
Versant Ventures V GP-GP (Canada), Inc. 10%+ Owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO Versant Ventures V GP-GP (Canada), Inc., By /s/ Max Eisenberg, Chief Operating Officer 2025-08-12 0001619297
Versant Ventures V (Canada), L.P. 10%+ Owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO Versant Ventures V (Canada), L.P., By Versant Ventures V GP-GP (Canada), Inc., its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2025-08-12 0001716490
Versant Venture Capital V (Canada), LP 10%+ Owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO Versant Venture Capital V (Canada), LP, By Versant Ventures V (Canada), L.P., its general partner, By Versant Ventures V GP-GP (Canada), Inc., its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2025-08-12 0001612235
Versant Vantage II GP-GP, LLC 10%+ Owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO Versant Vantage II GP-GP, LLC, By /s/ Max Eisenberg, Chief Operating Officer 2025-08-12 0001839789
Versant Vantage II GP, L.P. 10%+ Owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO Versant Vantage II GP, L.P., By Versant Vantage II GP-GP, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2025-08-12 0001839790
Versant Vantage II, L.P. 10%+ Owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO Versant Vantage II, L.P., By Versant Vantage II GP, L.P., its general partner, By Versant Vantage II GP-GP, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2025-08-12 0001832235

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSBX Common Stock Disposition pursuant to a tender of shares in a change of control transaction -2.73M -100% 0 Aug 8, 2025 By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Common Stock Disposition pursuant to a tender of shares in a change of control transaction -207K -100% 0 Aug 8, 2025 By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Common Stock Disposition pursuant to a tender of shares in a change of control transaction -90.9K -100% 0 Aug 8, 2025 By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Common Stock Disposition pursuant to a tender of shares in a change of control transaction -82K -100% 0 Aug 8, 2025 By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Common Stock Disposition pursuant to a tender of shares in a change of control transaction -275K -100% 0 Aug 8, 2025 By Versant Vantage II, L.P. F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Versant Ventures V, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.
F2 Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis ("Dr. Davis"), a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Versant V, and each disclaims beneficial ownership of the shares held by Versant V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F3 Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Dr. Davis, a member of the Issuer's board of directors, is a director of Canada V GP-GP. Each of Canada V GP-GP, Canada V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Canada V, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F4 Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Ophthalmic, and each disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F5 Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Affiliates V, and each disclaims beneficial ownership of the shares held by Affiliates, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F6 Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the sole general partner of Vantage II GP. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP. Each of Vantage II GP-GP, Vantage II GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Vantage II, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.